HEPATOCELLULAR CARCINOMA

This phase 2 trial is testing a combination of three drugs (cabozantinib, ipilimumab, and nivolumab) plus a procedure called TACE in 35 people with liver cancer that cannot be cured by surgery or transplant. The goal is to see if this approach can stop the cancer from growing for…

This early-stage trial tests a new drug, BAY 3547926, that delivers radiation directly to liver cancer cells with a specific protein (GPC3). The goal is to find a safe dose and see if it shrinks tumors. About 148 adults with advanced liver cancer will take part in four groups, so…

This study is for people with advanced liver cancer (hepatocellular carcinoma) who also have moderate cirrhosis (Child-Pugh B7 or B8). It tests the safety of two drugs, atezolizumab and bevacizumab, given together or alone as a first treatment. The goal is to see if these drugs a…

This study is testing a drug called patritumab deruxtecan in people with advanced gastrointestinal cancers that have spread. The drug is given through a vein and aims to shrink tumors. The trial will check how safe the drug is and how many people's cancers respond to treatment. A…

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

This phase 2 trial is testing whether adding common diabetes drugs (metformin or rosiglitazone) to standard immunotherapy (nivolumab or pembrolizumab) can improve treatment for several advanced solid tumors, including melanoma, lung cancer, and liver cancer. About 72 participants…

This early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …

This clinical trial is testing several combinations of immunotherapy drugs to see if they can shrink or control advanced liver cancer. The study is for people with a type of liver cancer called hepatocellular carcinoma (HCC) that has spread or cannot be removed by surgery. Partic…

This large Phase 3 trial is testing whether a new drug called rilvegostomig, combined with bevacizumab and with or without tremelimumab, can help people with advanced liver cancer live longer. About 1,220 participants who cannot have surgery or other local treatments will be rand…

This phase 2 trial tests whether adding lenvatinib to the STRIDE regimen (durvalumab plus tremelimumab) works better than STRIDE alone for people with advanced liver cancer that cannot be surgically removed. About 140 adults who have not had prior systemic therapy will be enrolle…

This study tests a new treatment called ECT204 for adults with advanced liver cancer that has not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The trial will enroll 60 pe…

This early-stage study tests a new type of cancer vaccine made from irradiated tumor and nearby cells. It aims to see if the vaccine is safe and can help the immune system fight advanced solid tumors like osteosarcoma, pancreatic cancer, and others. About 54 people will take part…

This study tests a new drug called PF-08634404, given alone or with another drug (ipilimumab), in adults with advanced liver cancer that cannot be surgically removed. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 138 participants will recei…

This phase 2 trial is testing whether an artificial intelligence system can find the best doses of three drugs (irinotecan, sonidegib, and sorafenib) for people with advanced liver cancer. The study will enroll 12 adults whose cancer has not responded to other treatments. The goa…

This program provides the experimental drug ulixertinib to people with advanced solid tumors that have certain gene mutations (MAPK pathway). It is for patients who have not responded well to or have run out of standard treatments. The goal is to control the disease and possibly …

This study tests whether a fecal microbiota transplant (FMT) can help liver cancer patients who stopped responding to standard drugs. Fifteen adults with advanced liver cancer will receive FMT along with atezolizumab and bevacizumab to see if the combination can restore tumor con…

This study is for adults with advanced liver cancer (hepatocellular carcinoma) that is hard to treat. It compares two standard drug regimens — immunotherapy (atezolizumab + bevacizumab) or targeted pills (lenvatinib or cabozantinib) — given after a liver-directed radiation treatm…

This study tests an experimental drug called LBL-024 combined with standard chemotherapy (cisplatin, gemcitabine) and bevacizumab in 140 people with advanced solid tumors. The goal is to see if the combination can shrink tumors and control the disease. Participants must be 18–75,…

This Phase 3 trial tests whether a chemotherapy infusion directly into the liver (HAIC) plus immunotherapy drugs works better than the standard chemo-embolization procedure (TACE) plus the same immunotherapy for people with intermediate-stage liver cancer that has spread extensiv…

This study is testing a combination of four drugs—atezolizumab, sorafenib, bevacizumab, and cyclophosphamide—in children and young adults with solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the combination can sh…

This pilot study tests a radioactive drug called 177Lu-PSMA-617 in 10 patients with PSMA-positive liver cancer that has spread. The goal is to see if the drug is safe and can shrink tumors. Patients must have already tried one prior treatment.

This early-stage trial is testing a new drug called ZW251 in about 100 people with advanced solid tumors, including liver cancer (hepatocellular carcinoma), a type of lung cancer (squamous cell non-small cell lung cancer), and germ cell tumors. ZW251 is an antibody-drug conjugate…

This study tests a new treatment plan for people with advanced liver cancer that has spread to blood vessels or a few other spots. The plan combines chemotherapy directly into the liver, two immunotherapy drugs, a targeted therapy, and precise radiation. The goal is to see if thi…

This early-phase trial tests a new approach for people with advanced liver cancer that cannot be removed by surgery. Doctors will freeze part of the tumor (cryoablation) and deliver an immune-boosting drug directly into the liver's blood supply. After that, participants receive t…

This study compares two treatments for advanced liver cancer (BCLC stage C): standard drug therapy alone versus drug therapy plus a precise type of radiation called stereotactic body radiotherapy (SBRT). The goal is to see if adding radiation helps people live longer. About 184 a…

This study tests a new oral drug called TTI-101 in people with advanced liver cancer that cannot be removed by surgery. The drug is given alone or combined with standard immunotherapy drugs. The main goals are to check safety and see if the drug shrinks tumors. About 193 adults w…

This early-phase study tests a new drug called IMC-002 in about 62 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can help control the cancer. Participants receive t…

This early-stage study tests a new drug called PF-08046054/SGN-PDL1V, alone or with another drug (pembrolizumab), in people with advanced solid tumors like lung, head and neck, esophageal, breast, stomach, endometrial, pancreatic, or liver cancer. The main goals are to find safe …

This early-phase trial tests a drug called tirapazamine, which becomes active only in low-oxygen (hypoxic) areas of tumors, combined with a standard procedure that blocks blood flow to the tumor (transarterial embolization). The goal is to find the best dose and see if the combin…

This phase 2 trial is testing several new immunotherapy drugs, alone or combined with standard chemotherapy, in people with advanced liver or bile duct cancer. The goal is to see if these combinations can shrink tumors or slow the disease. About 294 adults whose cancer has spread…

This study tests a two-step treatment for people with advanced liver cancer (hepatocellular carcinoma) or metastatic stomach cancer that has worsened despite prior immunotherapy. First, doctors deliver a drug called tirapazamine directly into the liver tumor through a procedure c…

This study tests whether adding a drug that blocks a cancer cell survival process called autophagy can make standard TACE therapy more effective for liver cancer. TACE cuts off the tumor's blood supply, but cancer cells often survive by eating their own parts for energy. The tria…

This study tests an experimental oral drug called Alintegimod (7HP349) combined with two standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, and liver cancers. The trial has two parts: first, finding a safe dose (p…

This early-stage trial tests a new drug called QXL138AM in about 100 people with advanced solid tumors (like ovarian, pancreatic, or lung cancer) or multiple myeloma. The drug is designed to help the immune system attack cancer cells. The main goal is to check safety and find the…

This study tests a new drug called CVM-1118 combined with an immunotherapy drug (nivolumab) in people with advanced liver cancer that cannot be removed by surgery. About 95 adults will take part to see if the combination shrinks tumors and how long any benefit lasts. The goal is …

This study tests a new drug called AZD9793 in people with advanced liver cancer that has spread. The drug is an antibody designed to help the body's immune cells find and attack cancer cells. The main goals are to check if the drug is safe and if it can shrink tumors. About 304 a…

This early-stage trial tests a new treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The study includes 38 adults with advanced solid tumors, such as liver cancer, who have not responde…

This early-stage study tests a new drug called ABSK-011 in about 200 people with advanced solid tumors, especially liver cancer that has not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Pa…

This study tests a genetically modified herpes virus (RP2) that infects and destroys cancer cells while also stimulating the immune system. It is given alone or together with standard drugs (bevacizumab, atezolizumab, or durvalumab) to 60 adults with advanced liver or bile duct c…

This phase 2 trial is testing enfortumab vedotin, a drug that delivers chemotherapy directly to cancer cells, in 40 adults with advanced colorectal or liver cancer that has worsened after standard treatments. The main goal is to see if the drug can shrink tumors. Researchers will…

This study is testing whether combining immunotherapy drugs (tremelimumab and durvalumab) with liver-directed procedures like TACE, TARE, or RFA can shrink liver cancer enough to make patients eligible for a liver transplant. The trial enrolls 41 adults with hepatocellular carcin…

This study is testing whether combining two drugs—Envafolimab (an immunotherapy injection) and Lenvatinib (a daily pill)—can shrink tumors in people with advanced solid cancers like lung, kidney, and liver cancer. About 170 adults whose cancer has worsened after standard treatmen…

This study tests whether adding the antidepressant fluoxetine (Prozac) to standard immunotherapy can improve tumor control and survival in 240 people with advanced liver or gallbladder cancer who also have depression or anxiety. Participants will receive either fluoxetine or a pl…

This study tests whether combining two drugs (atezolizumab and bevacizumab) with a type of internal radiation (Y-90) can shrink liver tumors enough for patients to become eligible for a liver transplant. About 40 adults with hepatocellular carcinoma (HCC) will receive this combin…

This study tests a newer, ultrasound-guided endoscopic technique to prevent repeat bleeding from enlarged veins in the stomach or esophagus of liver cancer patients. About 84 adults who recently had such bleeding controlled by standard endoscopy will be randomly assigned to recei…

This study tests whether adding a cancer vaccine (UCPVax) to standard immunotherapy (atezolizumab and bevacizumab) can shrink tumors better than standard therapy alone in people with advanced liver cancer that cannot be removed by surgery. About 105 adults who have not had prior …

This study tests whether taking prednisone, a steroid, before and during radiation therapy can protect the liver in people with liver cancer. About 20 participants will take prednisone for a short time around their radiation sessions. The goal is to see if it reduces liver inflam…

This study tests a new drug called AK112, alone or with other treatments, for people with advanced liver cancer that hasn't responded to standard care. The first part checks safety and the right dose, while the second part compares the new combinations to existing therapies. Abou…

This study tests a high-precision radiation treatment called SBRT for people with liver cancer who are waiting for a liver transplant but cannot have standard bridging treatments like radiofrequency ablation or chemoembolization. The goal is to see if SBRT can keep the cancer und…

This Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatme…

This early-phase study tests whether adding precise radiation (SBRT) to a standard two-drug combination (atezolizumab and bevacizumab) is safe and tolerable for people with advanced liver cancer that cannot be treated with surgery. The trial enrolls 18 participants and will also …

This early-stage trial tests a new type of immunotherapy for children and young adults with solid tumors that have not responded to standard treatments. The therapy uses the patient's own immune cells, which are genetically modified in the lab to recognize and attack cancer cells…

This Phase 3 trial tests whether giving a targeted chemotherapy treatment (TACE) after liver cancer surgery can prevent the cancer from coming back. It involves 442 patients with high-risk features for recurrence. Half will receive TACE, and the other half will have intensive mon…

This study tests whether a special nutritional drink taken for 7 days before liver surgery can improve recovery in 100 liver cancer patients. The drink contains ingredients like arginine and omega-3s that may support the immune system. Researchers will measure nutritional status,…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This trial tests whether adding liver-directed chemotherapy (GEMOX) to a two-drug immunotherapy regimen (durvalumab plus tremelimumab) improves outcomes for people with advanced liver cancer that has a high tumor burden. About 196 participants will be randomly assigned to receive…

This early-stage trial tests an experimental oral drug called CSCJC3456 in 102 people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any signs that the drug can shrink tumors. Participants take the table…

This early-phase trial is testing a new drug, BC2027, in 180 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors or slow their growth. Participants re…

This early-phase trial is testing an experimental drug called SIM0610 in 260 adults with advanced solid tumors, including lung, colorectal, head and neck, and liver cancers. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Particip…

This study is testing an anti-PD-1 antibody (a type of immunotherapy) alone or combined with low-dose decitabine and/or standard chemotherapy in people whose cancers have come back or not responded to treatment. The trial includes patients with several cancer types, such as lymph…

This early-phase study tests a new treatment called C-CAR031 for people with advanced liver cancer that has not responded to standard therapies. C-CAR031 uses a patient's own immune cells, modified to better target and attack cancer cells. The trial will enroll 72 participants to…

This study tests whether combining the targeted drug cabozantinib with immunotherapy drugs (durvalumab, with or without tremelimumab) is safe and effective for people with advanced stomach, esophageal, liver, or colorectal cancer. About 117 adults with stage 3 or 4 disease that c…

This study tests a new gel that hardens at body temperature to block blood flow to liver tumors during chemoembolization. About 216 adults with liver cancer will receive either the new gel or standard gelatin sponge particles. The goal is to see if the new gel better controls tum…

This early-stage trial is testing an experimental drug called DM005 in 136 people with advanced solid tumors, including lung, head and neck, and other cancers that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and se…

This phase 2 trial is testing whether giving two drugs—sintilimab (an immunotherapy) and bevacizumab (a targeted therapy)—before surgery can help prevent liver cancer from coming back. The study includes 37 adults with resectable liver cancer that is beyond the Milan criteria, me…

This study tests a combination of two experimental drugs, ZGGS18 and ZG005, in people with advanced solid tumors (cervical, liver, neuroendocrine, or lung cancer) that no longer respond to standard treatments. The main goals are to check safety, find the best dose, and see if the…

This study tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) in 32 people with advanced liver cancer who also have moderate cirrhosis (Child-Pugh B). The main goal is to see if the treatment is safe and tolerable, and to measure how well it shrinks tumo…

This study tests a new treatment called C-CAR031 for adults with advanced or recurrent liver cancer that has not responded to at least two prior therapies. C-CAR031 is made from a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells.…

This early-phase trial tests a special radiation technique called vGRID SBRT for people with liver cancer that cannot be surgically removed. The main goal is to find the highest safe dose and check for side effects. Up to 18 adults with advanced or metastatic liver cancer will re…

This study tests a new drug called YL242, given alone or with other treatments, for adults with advanced solid tumors that have not responded to prior therapy. The main goals are to check safety and see if tumors shrink. About 424 participants will take part in this early-phase t…

This early study tests whether giving focused radiation to a liver tumor a few weeks before surgery is safe and practical. The goal is to kill microscopic cancer cells around the tumor that often cause the cancer to return after surgery. Thirty patients with a single liver cancer…

This early-phase trial is testing a new drug called MT-303, alone or with two standard cancer drugs, in people with advanced liver cancer that has spread or cannot be removed. The main goals are to check safety, find the right dose, and see early signs of effectiveness. About 70 …

This study tests a drug called ADI-PEG 20 against a placebo in 300 people with advanced liver cancer that cannot be removed by surgery. Only people with high levels of the amino acid arginine in their blood can join. The goal is to see if the drug helps them live longer by breaki…

This early-stage trial tests a new drug called JMT106 in 200 people with advanced solid tumors, including lung and liver cancers, who have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shows any sign of shrinkin…

This study tests a combination of two types of drugs (anti-PD-1/PD-L1 and anti-VEGF) in 50 adults with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination is safe and helps shrink tumors or slow cancer growth. Participants will receive t…

This study tests a drug called cabozantinib in 20 adults whose liver cancer returned after a liver transplant. The goal is to see if the drug can control the cancer. Participants take the drug until it stops working or side effects become too bothersome.

This study is testing whether giving a PD-1 inhibitor (a type of immunotherapy) after microwave ablation can help prevent early-stage liver cancer from coming back. About 200 adults with early liver cancer will receive the drug every three weeks for nine cycles. The main goal is …

This study tests a precise type of radiation called carbon ion radiotherapy for people with liver cancer that remains or comes back after a prior treatment (TARE). About 48 adults will receive this targeted radiation, with doctors tracking how well it shrinks tumors and whether s…

This phase 2 trial tests whether adding a temporary oil-based embolization (lipiodol) to standard chemotherapy infusion through the liver artery can shrink tumors better while keeping the liver healthy. The study enrolls 24 adults with advanced liver cancer that cannot be surgica…

This study looks at whether giving the drug tislelizumab at different infusion times after surgery can help prevent liver cancer from coming back in high-risk patients. About 33 adults aged 18-75 with early-stage liver cancer who had curative surgery will take part. The main goal…

This study tests whether adding a precise type of radiation (carbon ion radiotherapy) to standard immunotherapy drugs (atezolizumab and bevacizumab) can better control advanced liver cancer. About 52 adults with liver cancer that cannot be surgically removed will receive this com…

This study monitors the safety and effectiveness of two drugs, Imjudo and Imfinzi, for people with liver cancer (hepatocellular carcinoma) in Korea. About 246 patients who are already eligible for these drugs under Korean guidelines will be observed in real-world settings. The go…

This early-stage trial tests an oral tablet called BB102 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a specific protein (FGFR4) that may help control cancer growth. The study will check safety, side effects, and how the dr…

This study tests whether adding two liver-directed treatments (chemoembolization and artery infusion) to standard immunotherapy can shrink tumors better in people with advanced liver cancer that cannot be removed by surgery. About 55 adults with good liver function and performanc…

This Phase 2 trial is testing whether a combination of three drugs—zanzalintinib, durvalumab, and tremelimumab—can shrink tumors in people with advanced liver cancer that cannot be removed surgically. The study will enroll 40 participants who have not received prior systemic ther…

This early-phase trial tests a new type of immunotherapy for adults with solid tumors that have a protein called GPC3 on their surface. Researchers take a patient's own T cells, add genes to help them recognize and attack GPC3-positive cancer cells, and also include a safety swit…

This study tests a combination of three drugs (atezolizumab, bevacizumab, and memantine) in 19 adults with advanced liver cancer that cannot be removed by surgery. The main goal is to see how many patients have their tumors shrink or disappear. Participants must be newly diagnose…

This study is testing whether memantine, a drug currently used for Alzheimer's disease, can help slow the growth of liver cancer in people with advanced cirrhosis. The trial will enroll 12 adults with liver cancer that cannot be removed by surgery and who are not candidates for s…

This phase 2 trial tests whether a single injection of IP-001, given right after standard liver cancer ablation or surgery plus ablation, can help keep the cancer from coming back. About 126 adults with intermediate to high risk of recurrence will be followed for at least two yea…

This study tests a new approach for people with liver cancer that has spread to the portal vein (the main blood vessel to the liver). Participants will receive radiation therapy before surgery, along with two drugs (camrelizumab and apatinib) before and after surgery. The goal is…

This phase II trial tests whether giving chemotherapy directly into the liver artery plus an immunotherapy drug (tislelizumab) before surgery, followed by more immunotherapy after surgery, can prevent liver cancer from returning in high-risk patients. The study enrolls 39 adults …

This phase 2 trial tests a personalized dendritic cell vaccine combined with the immunotherapy drug nivolumab in 60 people who had surgery for liver cancer or colorectal cancer that spread to the liver. The vaccine is made from each patient's unique tumor mutations and aims to tr…

This early-phase trial is testing a new therapy called Meta10-TIL for people with advanced solid tumors that have not responded to at least one prior treatment. The therapy uses a patient's own tumor-fighting immune cells, which are modified in the lab to work better, and then gi…

This early-phase trial is testing a new biologic drug called AWT020 in 60 adults with advanced solid tumors or lymphoma that have worsened after standard treatments. The main goals are to check the drug's safety at different doses and to see how the body processes it. Participant…

This early-phase trial is testing whether combining two immunotherapy drugs (durvalumab and tremelimumab) with targeted radiation (yttrium-90 microspheres) can safely shrink liver tumors before surgery. About 20 people with resectable hepatocellular carcinoma will receive the com…

This study is testing whether applying a radiofrequency device to the cut surface of the liver after tumor removal can reduce the chance of cancer returning at that spot. About 720 adults with liver cancer (either colorectal metastases or hepatocellular carcinoma) will be randoml…

This study is testing whether a blood test that looks for a marker called mSEPT9 can predict liver cancer in people with cirrhosis. Researchers will follow 400 patients for up to 5 years, taking blood samples every 6 months to see if changes in this marker signal cancer risk. The…

This study tests whether contrast-enhanced ultrasound (CEUS) can better detect if liver cancer (HCC) has been killed by radioembolization treatment. Standard CT or MRI scans often take months to show clear results, delaying further treatment. Researchers will enroll 30 patients a…

This study is testing whether proteins in the blood can help detect liver cancer at an early stage. Researchers will compare blood samples from 600 people—some with liver cancer and some healthy—to find protein patterns that signal the disease. The goal is to create a simple, non…

This study tests whether a new imaging agent called [18F]FAPI-74 can find certain cancers as well as or better than the standard PET tracer. About 320 adults with one of 11 cancer types (including pancreatic, liver, ovarian, and lung cancers) will receive both tracers and have th…

This early-phase study is testing whether a special PET scan using a drug called PYLARIFY can better detect cancer that has spread in people with pancreatic cancer, liver cancer, or breast cancer. About 36 adults will receive the scan, and doctors will compare the results to stan…

This study aims to develop a simple blood test that can tell the difference between two common types of liver cancer: hepatocellular carcinoma and cholangiocarcinoma. Researchers will analyze tiny particles called exosomes in the blood using machine learning. The goal is to help …

This study tests whether a new type of ultrasound, called quantitative ultrasound (QUS), can find liver cancers that standard ultrasound often misses. About 328 adults at risk for liver cancer will receive both QUS and standard ultrasound, and results will be compared to MRI or b…

This study compares adding a quick MRI scan (fast-MRI) to standard ultrasound every six months for detecting early-stage liver cancer in people with cirrhosis who are at high risk. About 944 participants will be randomly assigned to either ultrasound alone or ultrasound plus fast…

This study tests whether a shorter, contrast-enhanced MRI scan can detect liver cancer recurrence as well as standard CT scans in people who have been cancer-free for over two years after treatment. About 455 participants will receive both scans to compare their accuracy. The goa…

This study tests a new imaging tool that uses folic acid and carbon dots to make liver cancer cells glow. After surgery, the removed liver tissue is treated with these dots and scanned with a special camera. The goal is to see if this method can find cancer edges and tiny spots b…

This study is testing a blood test called Elecsys® GAAD to see if it can detect liver cancer earlier in people with liver cirrhosis. Current methods often find cancer too late, leaving few treatment options. The study will compare the GAAD test with standard care in 600 participa…

This study tests whether a 20-minute MRI scan without dye can detect liver cancer earlier than the usual ultrasound in 300 people with cirrhosis who are at high risk. Participants will get both scans every 6 months for 30 months. The goal is to see if the MRI catches cancers that…

This study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

This study looks at whether people with certain cancers prefer getting their immune therapy as a shot under the skin (subcutaneous) or through a needle in a vein (intravenous). About 880 adults who are already eligible for standard treatments like nivolumab or pembrolizumab will …

This study tests whether a dietary supplement called β-alanine can reduce fatigue in people with advanced liver cancer who are receiving standard immunotherapy. About 158 participants will take either the supplement or a placebo alongside their regular treatment. The main goal is…

This study looks at whether two types of liver cancer treatments—procedures done by radiologists or targeted radiation—can improve quality of life for patients who cannot have surgery. About 78 adults with liver cancer will fill out questionnaires before and after treatment. The …

This study tests whether a mushroom extract called Antrodia cinnamomea can help liver cancer patients recover liver function and improve quality of life after a procedure called transcatheter arterial chemoembolization (TACE). Sixty adults with liver cancer will take either the s…

This study investigates why some liver cancers respond to immunotherapy (atezolizumab plus bevacizumab) after surgery while others do not. Researchers will collect detailed molecular data from tumors and blood samples of 30 patients to find biomarkers that predict response, resis…

This study is observing 200 adults with advanced liver cancer who are starting a new treatment with two drugs, tremelimumab and durvalumab. Researchers want to see how long it takes for liver problems to get worse, how patients feel, and how safe the treatment is in everyday medi…

This study is testing whether a special PET scan (18F-FSPG) and a blood test for tumor DNA can help doctors better guide treatment for liver cancer. About 60 people with hepatocellular carcinoma will receive standard Y90 radioembolization therapy. The goal is to see if these test…

This study looks at how T cells (a type of immune cell) respond to liver cancer and cancers linked to Epstein-Barr virus (EBV) and human papillomavirus (HPV). About 105 participants will give blood and tissue samples once. Researchers will analyze these samples to identify cancer…

This study creates miniature, lab-grown versions of liver cancer tumors from patient biopsies. Researchers will test how well different treatments work on these models and look at how gut health and the tumor's environment affect the disease. The goal is to better understand live…

This study looks at whether the amount of healthy liver removed during surgery can predict liver failure afterward. Researchers will create a risk model based on 1,600 patients who had liver surgery for cancer. The goal is to help doctors identify high-risk patients before surger…

This study is recruiting 710 adults with fatty liver disease or alcohol-related liver disease, with or without cirrhosis, to understand why some develop liver cancer. Researchers will analyze genetic markers, immune factors, and imaging data from routine liver biopsies and blood …

This study looks at a method called 'Teaching the Teachers' to help spread liver cancer diagnosis guidelines. Experts learn the guidelines first, then teach other radiologists around the world. The goal is to see if this approach increases how often the guidelines are used. About…

This study aims to understand why many cancer patients lose muscle and fat (cachexia), a condition that worsens their health. Researchers will use advanced techniques to analyze samples from 1000 adults with certain cancers. The goal is to find early warning signs and new targets…

This study is observing 300 adults with kidney, bladder, lung, or liver cancer who are starting immunotherapy (PD-1/PDL-1 inhibitors). Researchers will measure a protein called Galectin-3 in the blood before each treatment to see if its level is linked to how well the therapy wor…

This study tests a personalized approach for patients with advanced liver or colorectal cancers that no longer respond to standard treatments. Doctors take a small sample of the tumor, grow it in the lab as 3D 'organoids', and test different drugs on them to see which works best.…

This study aims to find biological markers that can predict how well liver cancer patients respond to a combination of two immunotherapy drugs, tremelimumab and durvalumab. Researchers will follow 120 adults with advanced liver cancer who have not had prior systemic treatment. Th…

This study is looking for 500 people with certain cancers (like eye or skin melanoma, kidney cancer, or mesothelioma) and their family members to understand how common BAP1 gene mutations are. Researchers will collect medical history and questionnaires to learn about cancer risks…

This study explores whether using MRI scans before each radiation treatment is practical and helpful for people with liver or pancreatic cancer. About 30 participants will receive up to 5 extra MRIs alongside their standard radiation therapy. Researchers will measure patient sati…

This study looks at how the drug bulevirtide changes gut bacteria and bile acids in people with hepatitis delta (a serious liver infection). Researchers will follow 20 patients for 48 weeks, collecting stool and blood samples to see how these changes relate to liver health. The g…

This pilot study compares two ways of collecting blood to detect circulating tumor DNA (ctDNA) in people with liver or pancreatic cancers. Researchers will take blood from a standard arm vein and also from the vein that drains directly from the tumor during a biopsy. The goal is …

This study collects blood and tissue samples from 800 people with chronic liver disease or liver cancer. Researchers will use these samples to create lab models, such as cell clusters and mouse tumors, to study these diseases and test new treatments. The goal is to improve unders…

This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA) can predict if liver cancer will come back after surgery. Researchers will take blood samples before and after surgery, then at 3 and 6 months, from 150 adults with liver cancer. The goal is …

This study looks at why some people are diagnosed with liver cancer at a late stage, when treatment is harder. Researchers will survey 730 patients in Los Angeles about social and economic challenges like transportation, food, and housing. They will also interview doctors and com…

This study looks at whether CT scans can help doctors predict how well chemotherapy will work for people with pancreatic or liver cancer. About 259 adults with these cancers will get CT scans before and during treatment. The goal is to see if changes in the scan can tell if the t…

This study looks back at the medical records of 2000 people with liver cancer in Guangxi, China. Researchers want to find out which treatments given before surgery (called conversion or neoadjuvant therapy) work best to help patients live longer. The study includes treatments lik…

This study watches 50 people who already received a replimune oncolytic immunotherapy for cancers like melanoma or liver cancer. The goal is to check for any delayed side effects over 5 years. No new treatment is given—just regular check-ins to see how patients are doing.

This study looks at whether emotional disorders like depression and anxiety affect how well immunotherapy works in people with liver cancer. Researchers will follow 651 patients and compare treatment outcomes between those with and without emotional distress. The goal is to under…

This study is testing two scoring methods (PLEASE and M10S20) to see if they can better predict serious liver events, liver cancer, and death in 600 people with advanced chronic liver disease. Participants are randomly assigned to standard care or a risk-based monitoring schedule…

This study is for adults with advanced liver cancer who are starting a common immunotherapy combination (Atezolizumab and Bevacizumab). Researchers want to see if levels of a protein called Glypican-3 in the blood can help predict how well the treatment works. About 240 participa…

This study looks at how the bacteria in your gut might influence diarrhea caused by cancer treatments. Researchers will follow 150 adults starting cancer therapy, collecting stool and blood samples to analyze gut microbiome changes. The goal is to better understand why some peopl…

This study aims to find genetic differences that make some people with fatty liver disease develop severe liver damage or cancer. Researchers will analyze DNA from 2880 adults, including those with advanced disease and healthy controls. The goal is to create better risk tests and…

This study uses tiny, lab-grown liver models (organoids) made from patient cells to understand how a specific gene variant (I148M of PNPLA3) contributes to non-alcoholic steatohepatitis (NASH), a serious fatty liver disease. Researchers will expose these mini-livers to fatty acid…

This study looks at 300 liver cancer patients who cannot have surgery and instead receive a treatment called TACE. Researchers will use artificial intelligence to analyze routine CT scans taken before treatment, measuring body composition like muscle and fat. The goal is to creat…

This study collects and stores tissue and blood samples from people with stomach, esophageal, pancreatic, liver, and other gastrointestinal cancers. The goal is to build a large database of samples and medical information to help researchers understand these cancers better. Parti…

This study is collecting blood and tumor samples from 50 people with advanced liver cancer who are receiving immunotherapy. Researchers will analyze the samples to find genetic and immune system markers that might predict how well the treatment works. The goal is to better unders…

This study looks at medical records from 15,000 people to see how chronic liver diseases (like hepatitis, fatty liver, and cirrhosis) are linked to other health problems. Researchers will track new cases of liver cancer and complications over time. The goal is to better understan…

This study is collecting genetic and molecular data from up to 1,600 children with liver cancer and their families. Researchers will analyze DNA, gene activity, and immune cells to better understand what drives these rare tumors. The goal is to improve how these cancers are class…

This study will collect data from 1,500 people with liver tumors who are getting a procedure called thermal ablation, which uses heat to destroy tumors. Researchers will use artificial intelligence to analyze the data and find better ways to select patients, plan treatments, and …